Arylesterase activity of paraoxonase 1 (PON1) on HDL₃ and HDL₂: Relationship with Q192R, C-108T, and L55M polymorphisms

Sandra Y. Valencia Cᵃᵇᶜ*, Carlos A. Isaza Mᵈ, Julieta Henao Bᵈ, Leonardo Beltrán Aᵈᶠ, Nelsy Loango ᵇᶜ, Patricia Landázuri ᵇ

ᵃ Faculty of Health Sciences, Program of Nutrition, Universidad Libre, Colombia
ᵇ Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Colombia
ᶜ Faculty of Health Sciences, Universidad del Quindío, Colombia
ᵈ Faculty of Health Sciences, Universidad Tecnológica de Pereira, Colombia
ᵉ Faculty of Basic Sciences and Technologies, Universidad del Quindío, Colombia
ᶠ Faculty of Health Sciences, Universidad del Valle de Caldas, Colombia

ARTICLE INFO

Keywords:
HDL subfractions
HDL cholesterol
PON1 polymorphisms
Cardiovascular disease
Antioxidant
Arylesterase activity

ABSTRACT

Background: Controversy exists regarding the role of the subfractions of high-density lipoproteins (HDL₃ and HDL₂) in cardiovascular disease. The functionality of these particles, and their protective role, is due in part to the paraoxonase 1 (PON1) presence in them. The polymorphisms rs662 (Q192R, A/G), rs854560 (L55 M, T/A), and rs705379 (C-108T) of the PON1 gene have been related to enzyme activity and, with the anti-oxidative capacity of the HDL. The objective was to determine the arylesterase PON1 activity in HDL₃ and HDL₂ and its relationship with the polymorphisms mentioned, in a young population.

Methods: The polymorphisms were determined through mini-sequencing (SnaPshot). The HDL subpopulations were separated via ionic precipitation, cholesterol was measured with enzymatic methods, and PON1 activity was measured through spectrophotometry.

Results: The results show that the PON1 polymorphisms do not influence the cholesterol in the HDL. A variation between 40.02 and 43.9 mg/dL was in all the polymorphisms without significant differences. Additionally, PON1 activity in the HDL₃ subfractions was greater (62.83 ± 20 kU/L) than with HDL₂ (35.8 ± 20.8 kU/L) in the whole population and in all the polymorphisms (p < 0.001), and it was independent of the polymorphism and differential arylesterase activity in the Q192R polymorphism (QQ > QR > RR). Thus, 115.90 ± 30.7, 88.78 ± 21.3, 65.29 ± 10.2, respectively, for total HDL, with identical behavior for HDL₃ and HDL₂.

Conclusions: PON1 polymorphisms do not influence the HDL₃, and the PON activity is greater in the HDL₂, independent of the polymorphism, but it is necessary to delve into the functionality of these findings in different populations.

1. Introduction

The HDL exert potent anti-atherogenic activities, which include anti-oxidative and anti-inflammatory actions, which are relevant in attenuating the progression of atherosclerosis [1–3]. The anti-atherogenic functions of HDL lie directly in their composition and structure; however, the impact and mechanisms through which they exert these functions has not been clearly established.

The HDL are a heterogeneous group of particles that differ in their composition of lipids, apolipoproteins, size, density, and charge, which in turn gives them different properties [4]. Epidemiological studies have shown that low concentrations of cholesterol in HDL (HDL₃) constitute an important and independent risk factor of cardiovascular disease; however, recent evidence indicates that changes in the distribution of the HDL subclasses and of their component proteins, such as the PON1, are of greater utility than the concentrations of HDL₃ in predicting coronary events [5].

Diverse subHDL populations are generated in the plasma. Initially, HDL are synthesized and secreted from the liver and intestine as nascent particles of pre-β HDL, formed predominantly by the apoprotein A-I (ApoA-I) and phospholipids. In circulation, more phospholipids, cholesterol, and other minority apoproteins, like the PON1, are added,
thus forming the diverse subHDL populations. Various systems are used to classify and separate the different populations or subfractions of plasma HDL \[6\]; one of them is the precipitation method that separates HDL into two principal subfractions, HDL$_2$ and HDL$_3$. The HDL$_2$ is a less-dense particle (d 1.063–1.125 g/ml), which is bigger and enriched with cholesterol esters; the HDL$_3$, or helical, is a more-dense particle (d 1.1251.21 g/ml), which is small and relatively rich in proteins \[7\].

The PON1, classified as an arylalkylphosphatase enzyme (EC 3.1.8.1) \[8\], is a glycoprotein with anti-atherogenic and anti-oxidant properties and is strongly bound to HDL \[9\]; it is a promiscuous enzyme that can hydrolyze various substrates, among them paraoxon (diethyl p-nitrophenyl phosphate) from which is derived its name, but which also has lactonase and arylesterase activities. With this last activity, it hydrolyzes oxidized lipids from low-density lipoproteins (LDL) \[10,11\]. Additionally, strong evidence indicates that PON1 can exert its atheroprotective effect by regulating cholesterol flow from the macrophages and maintaining this lipid’s homeostasis \[12\].

The PON1 activity may be affected by diverse factors, including lifestyle, diseases such as diabetes and obesity, and its polymorphisms. In this last aspect, various polymorphisms have been described for this enzyme, among which are C-108T and L55 M that seem to modify the enzymatic activity and concentration and Q192R, which modifies its activity \[13,14\].

These polymorphisms have been broadly studied and related with cardiovascular disease, but few studies describe the relationship of these genetic variants with enzyme activity in the HDL$_2$ and HDL$_3$ subfractions in a healthy, young population; hence, the objective of this study was to determine, in a population of young individuals without diagnosed disease, arylesterase PON1 activity in the HDL subfractions and its relationship with the enzyme’s polymorphisms.

2. Methods

Type of study: Descriptive non-experimental.

Population: Males between 18 and 35 years of age who were students and administrative staff from universities in the Colombian coffee region, without diagnosed disease, and with no blood relation to each other. The study excluded smokers and extreme and elite athletes, as well as individuals taking any medication or with diabetes mellitus, cardiovascular disease, liver or kidney damage, or nutritional or collagen disorders.

Sample: The blood sample was taken by venipuncture after 12 h of fasting. The serum was obtained by centrifuging at 1,500 g for 8 min and stored at -80 °C until its analysis.

DNA isolation and genotyping: Three polymorphisms were studied: rs662 (Q192R), rs854560 (L55 M), and rs705379 (C108T). Genomic DNA was extracted by using the Kit by Promega; amplification was done on three fragments of the PON1 gene. An initial polymerase chain reaction (PCR) was conducted in a total volume of 10 μL, which contained 1–10 ng of DNA, 1X Qiagen Multiplex PCR Master Mix, and 0.2 μM of each of the primers (Table 1). Temperature conditions for the PCR were 95 °C for 15 min, followed by 35 cycles of amplification at 94 °C for 1 min, 60 °C for 90 s, and 72 °C for 50 s, with a final extension at 72 °C for 7 min. Excess primers and nucleotides were removed by adding 1 μL of ExoSAP-IT (Affimatrix) to 2.5 μL of the PCR product. Thereafter, SNP detection was conducted with the mini-sequencing method. By using the PCR product as a template, multiplex reactions were carried out to detect the SNPs, in a 6-μL volume, which contained 1.5 μL of PCR product, 1 μL of Snapshot Reaction Mix (Applied Biosystems), and 3.5 μL of the mixture of SBE (Single Base Extension), primers with 0.2 μM concentration (Table 1). The amplification was conducted with 35 cycles at 96 °C for 10 s, 50 °C for 5 s, and 60 °C for 30 s. For detection, 2 μL of this product were mixed with 9 μL of HiDi- formamide and 0.5 μL of GeneScan-120Liz Internal Size Standard (Applied Biosystems) and were read in the ABI sequencer Prims 3100-Avant Genetic Analyzer (Applied Biosystems). Data were analyzed according to the color of the peaks and size of fragments, through Genemapper software v3.2 (Applied Biosystems). The presence of polymorphisms was confirmed by resequencing selected samples.

HDL$_2$ and HDL$_3$ subfractions separation: Total HDL (HDL$_t$) was isolated by using the procedure of the Human Kit for HDL-cholesterol. That is, 1 mL of diluted Human-HDL-cholesterol reagent (4 ml of HDL reagent and 1 ml of water) was added to 500 μL of plasma; this was incubated for 10 min and centrifuged for 7 min at 3,000 g. The very low density lipoproteins (VLDL) and LDL chylomicrons remained in the supernatant and the HDL$_2$ and HDL$_3$ in the supernatant. To separate these from the supernatant, dextran sulfate-Mg$^{2+}$ was added, according to the methods described by Warnick et al. \[15\], with some modifications made by García-Cardona et al., \[16\]. To briefly explain, 50 μL of dextran sulfate-Mg$^{2+}$ (2% dextran + 9.49% MgCl$_2$ 50–50 proportion) were added to a volume of 450 μL of the previous supernatant; this was agitated in a vortex and left to rest for 20 min and centrifuged at 13000 rpm; the precipitate corresponds to the HDL$_2$ lipoproteins, and the supernatant to the HDL$_3$.

2.1. Total cholesterol (HDL$_{c3}$) HDL$_2$ cholesterol (HDL$_{c2}$), and HDL$_3$ cholesterol (HDL$_{c3}$)

An aliquot was taken from the two previous supernatants, and HDL$_{c}$ was determined with the commercial kit, following manufacturer’s instructions (Human). The HDL$_2$ cholesterol was calculated by subtracting HDL$_{c3}$ from HDL$_{ct}$.

2.2. PON1 activity

The arylesterase activity in each of the HDL subfractions was determined by using phenyl acetate as substrate with the method reported by Carranza et al. \[17\], with modifications. To 5 μL of the sample was added 995 μL of Buffer 12 mM-Tris-HCL, pH 8, with phenyl acetate 1 mM as substrate, 1.6 mM CaCl$_2$ and Ethylenediaminetetraacetic acid (EDTA) 6 μM at 37 °C. Enzyme activity was calculated by using the phenol molar extinction coefficient (1.3 × 103 L*mol$^{-1}$*cm$^{-1}$). Absorbance was measured at 270 nm. The arylesterase activity was expressed as mMol of hydrolyzed phenyl acetate per min per L of serum (kU/L) \[18,19\].

2.3. Statistical analysis

The allele frequencies were calculated from the number observed from each allele. The Hardy-Weinberg equilibrium was established through the Chi-squared test, which was also used to compare

### Table 1

| SNP     | Forward (5′-3′) | Reverse (5′-3′) | SBE (5′-3′) |
|---------|-----------------|-----------------|-------------|
| rs662   | GAGATTTCATTTTTCCTAA | TTCCTCATGTCTATTCC | CTAACCCAAATCTACATCecAGGAT |
| Gln192Arg | TTGAAGTGGGCTGATGAT | TGATCCACTATCTACInAATA | GTCCTCACAGGcCAGTTTC |
| rs854560 | GCCAGCCGCCTGCAGGG | GAAAGGAGCAAAATGGGGACT | TGCTGGGCGAGGCGGCGATCGG |
| Leu55Met | C-108T          |                  |             |
Qualitative variables. The analysis of variance (ANOVA) was used for the correlations among the genotypes and the HDL or the enzymatic activity, while the correlations between lipid fractions and enzymatic activity were established through the Pearson correlation. Statistical analyses were performed with the SPSS 19 software for Windows, using 95% confidence intervals and considering values of \( p < 0.05 \) as significant.

3. Results

3.1. Anthropometric characteristics and HDL-c description of the study population

This part of the study included 133 individuals, whose anthropometric characteristics and concentration of total HDL-c are described in Table 2.

3.2. Genotypic and allelic distribution

Table 3 describes the genotypic and allelic distribution of the three polymorphisms studied. The three were in Hardy-Weinberg equilibrium and no linkage imbalance was evident.

3.3. HDL cholesterol

Table 4 shows the cholesterol distribution in total HDL in the distinct polymorphisms.

The data indicate no significant variation of the HDL-c in the different polymorphisms, which is corroborated with the correlation indicated in Table 5 that shows data of statistical significance among the genotypes, diplootypes, and haplotypes, and the HDL-c concentration. These values indicate that no correlation was found among them.

3.4. PON1 activity in the HDL subfractions and genetic polymorphisms

This study related the activity of the PON1 enzyme from only 78 of the 133 individuals in the HDL subfractions, with the genetic polymorphisms from the same enzyme; the results are evidenced in Table 6.

First, the results show that, in the three polymorphisms, the arylesterase PON1 activity is greater in the HDL\(_2\) than in the HDL\(_3\); secondly, the data indicate that only in the Q192R polymorphism, the enzyme activity in the three HDL populations behave; thus, PON1 activity in QQ > QR > RR with significant differences (Fig. 1).

The study also evaluated the correlation of the combination of polymorphisms and their effect on the PON1 activity in each HDL subfraction; the results are shown in Table 7. These indicate that significance was only evident in the combinations with the Q192R polymorphism present.

4. Discussion

The PON1 is a promiscuous enzyme that can hydrolyze various substrates, like organophosphate compounds, arylesters, cyclic thiolactone carbonates, nerve gas, glucuronides, and estrogen esters [14]. With respect to cardiovascular disease, however, it seems that its principal substrate are peroxides and lipophilic lactones associated with lipoproteins, especially LDL, thus preventing the oxidation of this lipoprotein, given that these oxidized lipids are pro-atherosclerotic and pro-inflammatory [10–12].

In addition, the PON1 is a polymorphic enzyme, and the enzyme’s genetic variations can modify its properties in serum or plasma. The gene has various polymorphisms in the coding region, with the principal and most studied being the rs662 (Q192R) and the rs854560 (L55 M). The enzyme also has diverse polymorphisms in the promoter region, among them, the rs705379 (-108C/T) [20–22].

This work researched the polymorphisms mentioned (Q192R, L55 M, and C-108T). The results show that the allelic and gene frequencies of these polymorphisms (Table 3) do not differ much from those found in the North American [23], Latin [24,25], and even Colombian populations [26].

It was interesting to find that although the PON1 is an enzyme strongly bound to HDL, none of its three polymorphisms influenced the cholesterol concentration in these lipoproteins (Table 4 and 5), given that HDL-c was similar in all the genotypes of the three polymorphisms studied.

The literature shows that the metabolism of HDL involves a complex network of factors that regulate their synthesis, intravascular remodeling, and catabolism; their components in lipids and apoproteins assembled after their secretion (through liver and intestine) are frequently interchanged or transferred to other lipoproteins, giving way to a family of HDL subfractions with similar components (lipids, proteins), but not in the same amount and composition and, hence, do not seem to have the same properties [21,27–29]. Among the protein components of the HDL subpopulations, there are the APOA (its principal apoprotein) and the PON1. This latter enzyme has been more associated with the anti-oxidative and anti-inflammatory capacity of the HDL subclasses than with its cholesterol content [9,13,21,22].

This work also evaluated the arylesterase PON1 activity in the subpopulations’ HDL in each of the genotypes of the three polymorphisms (Table 6). The results provide evidence for three important findings: first, the arylesterase activity of the PON1 enzyme was similar in the three polymorphisms; second, when comparing the HDL\(_3\) and HDL\(_2\), the activity was greater in the HDL\(_2\) in all the polymorphisms; and third, only in the Q192R polymorphism was the arylesterase enzyme activity distributed; thus, QQ > QR > RR, with significant differences in the three subfractions studied (HDL\(_3\), HDL\(_2\), and HDL\(_1\)). But, besides, when combining the polymorphisms and relating them with the enzyme activity, only the presence of the Q192R polymorphism showed significance with the PON1 activity (Table 7).

The last results confirm data described by other authors showing that enzyme activity depends more on the Q195R polymorphism than on the other two polymorphisms studied [8,14,31]. The literature also describes that the Q192R polymorphism in the PON1 is the principal determining factor in enzyme activity (especially paraoxonase activity), with greatest activity in the QQ genotype, with a marked difference in comparison with the QR and RR [8,14]. These results are similar to those found in our work on the PON’s arylesterase activity; however, it must be noted that some authors have found influence from the L55 M and C-108T polymorphisms in PON1 activity and expression [13,23].

This study was relevant in that it demonstrated that, in the three polymorphisms studied, the HDL\(_3\) subfraction has greater PON activity than the HDL\(_2\), given that few works describe this finding in the three polymorphisms simultaneously. Also, data from this work suggest that the greater PON1 activity in the HDL\(_3\) is independent of the polymorphism. Similar results were found by Schiavo et al. [32] in patients with chronic kidney disease, showing that greater PON1 activity was present in the HDL\(_3\) in both patients and controls, but that in the patients this activity was significantly lower, independent of the polymorphism. Our data and that of this and other authors suggest there is greater PON

### Table 2

Anthropometric characteristics and HDL-c of the study population.

| Characteristic          | Value    |
|------------------------|----------|
| Age (years)            | 20.8 ± 2.2 |
| Weight (kg)            | 71.40 ± 15.38 |
| Height (m)             | 1.8 ± 0.1 |
| Body mass index (Kg/m\(^2\)) | 23.4 ± 4.6 |
| HDL\(_2\) (mg/dL)      | 42.85 ± 9.20 |
| PON1-HDL\(_3\) (kU/L)  | 96.9 ± 30 |
| PON1-HDL\(_2\) (kU/L)  | 62.8 ± 20.2 |
| PON1-HDL\(_1\) (kU/L)  | 35.8 ± 20.2 |

HDL-c: high-density lipoprotein cholesterol; PON1 = Paraoxonase 1.
no activity in the HDL3 and that this is independent of the polymorphism and depends more on the normal or abnormal physiology of the individuals [18].

Greater PON1 activity in the HDL3 agrees with its normal physiology, given that once the enzyme is synthesized in the liver and secreted to the bloodstream, it binds to nascent HDL3; during HDL maturation, the PON1 is activated and shows a flow toward smaller and larger HDL3 and depends more on the normal or abnormal physiology of the individuals [18].

Next to the theory of formation of HDL subfractions, in which HDL2 are formed from HDL3 by exchange of lipids and proteins (including PON1), it is suggested that in healthy subjects, PON1 remains in HDL3 to meet an antioxidant function and does not remain in the HDL3 to be recycled and carry them to the liver by the reverse transport of cholesterol (TRC) [18,33,34], a theory that can be supported by our data and that of other authors who have found greater activity in HDL3 than in HDL2 [32,35,36].

Although the function of HDL3 in cardiovascular disease, sedentary habits, and some metabolic disorders is controversial, given that 16 authors have assigned it a protective role and others have not [16,37,38], the evidence shown in this work and in others of greater enzyme activity in this subfraction would agree with its athero-protective function because the PON1 activity has been assigned functions, like the activation of the endothelial nitric oxide synthase, prevention of lipid oxidation and hydrolysis of oxidized lipids in the LDL, and reduction of foam-cell formation among other functions related with the ECV [8,20].

Hence, we can suppose that if the HDL3 have the greatest PON1 activity in the HDL3 and that this is independent of the polymorphism and depends more on the normal or abnormal physiology of the individuals [18].

Greater PON1 activity in the HDL3 agrees with its normal physiology, given that once the enzyme is synthesized in the liver and secreted to the bloodstream, it binds to nascent HDL3; during HDL maturation, the PON1 is activated and shows a flow toward smaller and larger HDL3 and depends more on the normal or abnormal physiology of the individuals [18].

According to the theory of formation of HDL subfractions, in which HDL2 are formed from HDL3 by exchange of lipids and proteins (including PON1), it is suggested that in healthy subjects, PON1 remains in HDL3 to meet an antioxidant function and does not remain in the HDL3 to be recycled and carry them to the liver by the reverse transport of cholesterol (TRC) [18,33,34], a theory that can be supported by our data and that of other authors who have found greater activity in HDL3 than in HDL2 [32,35,36].

Although the function of HDL3 in cardiovascular disease, sedentary habits, and some metabolic disorders is controversial, given that 16 authors have assigned it a protective role and others have not [16,37,38], the evidence shown in this work and in others of greater enzyme activity in this subfraction would agree with its athero-protective function because the PON1 activity has been assigned functions, like the activation of the endothelial nitric oxide synthase, prevention of lipid oxidation and hydrolysis of oxidized lipids in the LDL, and reduction of foam-cell formation among other functions related with the ECV [8,20].

Hence, we can suppose that if the HDL3 have the greatest PON1
activity, they are protective against the oxidative damage of LDL; hence, they serve as an anti-atherosclerotic factor, although their clinical relevance is still under debate. But HDL also could have a protective role, due to their role in TRC, but the balance between one and another will depend on the state of the organism. Whether or not the protective function of HDL, given their anti-oxidative capacity, is complementary or contrary to the function of HDL due to their role in cholesterol transport needs further research in healthy individuals with diverse pathologies and in follow-up studies.

A great limitation of this study is that the paraoxonase activity and the salt-stimulated paraoxonase activity were not measured, which implies that an antioxidant capacity of the enzyme was not measured, however, several authors have not found significant differences between the activity paraoxonase and arylesterase activity in various populations including in the Harangi et al. study in dyslipidemic patients and controls (38).

5. Conclusion

Our data show that although the PON is an enzyme closely associated with HDL, the cholesterol concentration in them is independent of the polymorphisms. Moreover, it is confirmed that the Q192R polymorphism determines – in part – the PON1 activity and that its effect is mediated by the Q allele, given that this allele seems to have greater activity than the R. Likewise, this work demonstrates that the arylesterase activity of the PON1 is higher in the HDL3 subfractions than in the HDL2 and that this activity in the subfractions is independent of the polymorphisms.

Ethics approval and consent to participate

The research was approved by the institutional Bioethics Committee (Acta No. 31 Punto 03 Numeral 3.2.2–2016). All participants signed an informed consent, prior to blood sample.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was financially supported by a grant from the Universidad del Quindío, with the support of the Universidad Tecnológica de Pereira, Universidad Libre and Fundación Universitaria Autónoma de las Americas.

Credit author statement

Sandra Y. Valencia C.: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Resources, Data Curation, Writing - Original Draft, Visualization, Supervision, Project administration, Funding acquisition

Julieta Henao: Methodology, Validation, Investigation, Resources, Supervision, Project administration, Funding acquisition

Leonardo Beltrán: Methodology, Validation, Investigation, Funding acquisition

Nelsy Loango: Methodology, Validation, Investigation, Writing - Original Draft, Project administration, Funding acquisition

Patricia Landazuri: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Resources, Data Curation, Writing - Original Draft, Visualization, Supervision, Project administration, Funding acquisition.

Declaration of competing interest

The authors declare no competing financial interests.

Acknowledgments

We thank to laboratories in Universidad del Quindío, and Universidad Tecnológica de Pereira. for providing technical services.

References

[1] L.J. Leberkühne, S. Ebrahj, L.G. Dimova, A. Dikkers, R.P.F. Dullaart, S.J.L. Bakker, et al., The predictive value of the antioxidative function of HDL for cardiovascular disease and graft failure in renal transplant recipients, Atherosclerosis 249 (2016) 181–185.

[2] M. Navab, G.M. Ananthramaiah, S.T. Reddy, B.J. Van Lenten, B.J. Ansell, G. C. Fonarow, et al., The oxidation hypothesis of atherogenesis: the role of oxidized phospholipid and HDL, J. Lipid Res. 45 (6) (2004) 993–1007.

[3] M. Hussein, S. Saheb, M. Costurier, M. Atassi, A. Orsoni, A. Carrié, et al., Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: partial correction by low-density lipoprotein apheresis, J. Clin. Lipidol. 10 (1) (2016) 124–133.

[4] L. Camon, M.J. Chapman, A. Konrath, Biological activities of HDL subpopulations and their relevance to cardiovascular disease, Trends Mol. Med. 17 (10) (2011) 594–603.

[5] B.F. Atrazis, D. Collins, L.A. Culples, S. Denisie, K.V. Horvath, H.E. Bloomfield, et al., Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial, Arterioscler. Thromb. Vasc. Biol. 25 (10) (2005) 2185–2191.

[6] A. Haftane, J. Genest, High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk, BBA Clin. 3 (2015) 175–188.

[7] S. Gangjli, A.A. Montamonti-Borjonjii, M. Banach, P.T. Kovanen, A.M. Goto, A. Sahebkar, HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions, Drug Discov. Today 23 (1) (2018) 171–180.

[8] A. Mahrooz, M. Mackness, A. Bagheri, M. Ghaffari-Cherati, P. Masoumi, The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: the missing link between environmental and genetic regulation, Clin. Biochem. 73 (2019) 1–10.

[9] C.E. Furlong, J. Marsillach, G.P. Jarvik, L.G. Costa, Paraoxonases-1, -2 and -3: what are their functions? Chem. Biol. Interact. 259 (2016) 51–62.

[10] K. Kuppan, J. Mohanlal, A.M. Mohamad, K.A. Babu, P. Sen, Undurti N. Das, et al., Elevated serum OxLDL is associated with progression of type 2 Diabetes Mellitus to diabetic retinopathy, Exp. Eye Res. 186 (2019) 107668.

[11] J. Vekic, J. Kotur-Stevuljvic, Z. Jelic-Ivanovic, S. Spasic, V. Spanojevic, Kalimanovska, A. Topic, et al., Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects, Eur. J. Clin. Invest. 37 (9) (2007) 715–723.

[12] H. Berrougui, S. Louden, A. Khalil, Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol eflux from macrophages, Free Radic. Biol. Med. 52 (8) (2012) 1372–1381.

[13] M. Mackness, B. Mackness, Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles, Gene 567 (1) (2015) 12–21.

[14] A. Tajbakhsh, M. Rezaee, M. Rivandi, A. Afzaljavan, A. Pasdar, Paraoxonase 1 (PON1) and stroke; the dilemma of genetic variation, Clin. Biochem. 50 (18) (2017) 1298–1305.

[15] M.B. Warnik, J. Benderzon, J.J. Albers, Dextran sulfate-Mg2 precipitation procedure for quantitation of high- density lipoprotein cholesterol, Clin. Chem. 28 (6) (1982) 1379–1388.

[16] D.M. García-Cardona, O.A. Nieto, P. Landázuri, Efecto del ejercicio sobre las subpoblaciones HDL, la enzima lecitina-colesterol acil-transferasa y la proteína transportadora de ésteres de colesterol en estudiantes de Medicina, Rev. Colomb. Cardiol. 22 (6) (2015) 277–284.

[17] E. Carranza, C. F. Paez, ARTICULO ORIGINAL Distribución del polimorfismo Q192R del gen de la paraoxonasa 1 en una población Distribución del Q192R.
polymorphism of the paraoxonase 1 gene in a population of the district of Junín (Junín region, Peru), Horizons Medicaux 17 (2) (2017) 30–37.

18 C. Cervellati, G.B. Vigina, A. Trentini, J.M. Sanz, F. Zimetti, E. Dalla Nora, et al., Paraoxonase-1 activities in individuals with different HDL circulating levels: implication in reverse cholesterol transport and early vascular damage, Atherosclerosis 285 (2019) 64–70.

19 C. Cervellati, A. Trentini, A. Romani, T. Bellini, C. Bosi, B. Ortolani, et al., Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: a pilot study, J. Neurochem. 135 (2) (2015) 395–401.

20 M. Mackness, B. Mackness, Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles, Gene 567 (1) (2015) 12–21.

21 A. Gugliucci, Activation of paraoxonase 1 is associated with HDL remodeling ex vivo, Clin. Chim. Acta 429 (2014) 38–45.

22 A. Gugliucci, T. Menini, Paraoxonase 1 and HDL maturation, Clin. Chim. Acta 439 (2015) 5–15.

23 V.H. Brophy, R.L. Jampsa, J.B. Clendenning, L.A. McKinstry, G.P. Jarvik, C. A. Gugliucci, T. Menini, Paraoxonase 1 and HDL maturation, Redox Biol. 24 (2019) 101222.

24 M. Mackness, B. Mackness, Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles, Gene 567 (1) (2015) 12–21.

25 A. Gugliucci, Activation of paraoxonase 1 is associated with HDL remodeling ex vivo, Clin. Chim. Acta 429 (2014) 38–45.

26 A. Gugliucci, T. Menini, Paraoxonase 1 and HDL maturation, Clin. Chim. Acta 439 (2015) 5–15.

27 S.S. Martin, S.R. Jones, P.P. Toth, High-density lipoprotein subfractions: current views and clinical practice applications, Trends Endocrinol. Metab. [Internet] 25 (7) (2014) 329–336.

28 Y. Zhang, S.M. Gordon, H. Xi, S. Choi, M.A. Paz, R. Sun, et al., HDL subclass proteomic analysis and functional implication of protein dynamic change during HDL maturation, Redox Biol. 24 (2019) 101222.

29 E. Zakiev, F. Rached, M. Lhomme, M. Darabi-Amin, M. Ponnaiah, P.H. Becker, et al., Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency, J. Clin. Lipidol. [Internet] 13 (3) (2019) 468–480, e8.

30 R. Schiavon, P. Battaglia, E. De Fanti, A. Fasolin, S. Biasioli, L. Targa, et al., HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism, Clin. Chim. Acta 324 (1–2) (2002) 39–44.

31 M. Lee-Rueckert, J.C. Escola-Gil, P.T. Kovanen, HDL functionality in reverse cholesterol transport - challenges in translating data emerging from mouse models to human disease, Biochim. Biophys. Acta 1861 (7) (2016) 566–583.

32 A. Oberbach, V. Adams, N. Schlüchting, M. Heinrich, Y. Kullnick, S. Lehmann, et al., Proteome profiles of HDL particles of patients with chronic heart failure are associated with immune response and also include bacteria proteins, Clin. Chim. Acta 453 (2016) 114–122.

33 M. Mikkovic, A. Stefanovic, J. Vekic, A. Zeljkovic, T. Gojkovic, S. Simic-Ogrizovic, et al., Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease, Clin. Biochem. 60 (2018) 52–58.

34 M.C. Bakogianni, C.A. Kalofoutis, K.I. Skenderi, A.T. Kalofoutis, Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease, J. Diabet. Complicat. 15 (5) (2001) 265–269.

35 M.C. Bakogianni, C.A. Kalofoutis, K.I. Skenderi, A.T. Kalofoutis, Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease, J. Diabet. Complicat. 15 (5) (2001) 265–269.

36 M. Umaerus, B. Rosengren, B. Fagerberg, E. Hurt-Camejo, G. Camejo, HDL2 interference with LDL association with arterial proteoglycans: a possible athero-protective effect, Atherosclerosis 225 (1) (2012) 115–120.

37 J.J. Albers, A. Slez, J.L. Fleg, K.D. O’Brien, S.M.Marcovina, Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial, Atherosclerosis 251 (2016) 454–459.

38 Y. Zhang, S.M. Gordon, H. Xi, S. Choi, M.A. Paz, R. Sun, et al., HDL subclass proteomic analysis and functional implication of protein dynamic change during HDL maturation, Redox Biol. 24 (2019) 101222.

39 E. Zakiev, F. Rached, M. Lhomme, M. Darabi-Amin, M. Ponnaiah, P.H. Becker, et al., Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency, J. Clin. Lipidol. [Internet] 13 (3) (2019) 468–480, e8.

40 R. Schiavon, P. Battaglia, E. De Fanti, A. Fasolin, S. Biasioli, L. Targa, et al., HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism, Clin. Chim. Acta 324 (1–2) (2002) 39–44.

41 M. Lee-Rueckert, J.C. Escola-Gil, P.T. Kovanen, HDL functionality in reverse cholesterol transport - challenges in translating data emerging from mouse models to human disease, Biochim. Biophys. Acta 1861 (7) (2016) 566–583.

42 A. Oberbach, V. Adams, N. Schlüchting, M. Heinrich, Y. Kullnick, S. Lehmann, et al., Proteome profiles of HDL particles of patients with chronic heart failure are associated with immune response and also include bacteria proteins, Clin. Chim. Acta 453 (2016) 114–122.

43 M. Mikkovic, A. Stefanovic, J. Vekic, A. Zeljkovic, T. Gojkovic, S. Simic-Ogrizovic, et al., Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease, Clin. Biochem. 60 (2018) 52–58.

44 M.C. Bakogianni, C.A. Kalofoutis, K.I. Skenderi, A.T. Kalofoutis, Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease, J. Diabet. Complicat. 15 (5) (2001) 265–269.

45 M. Umaerus, B. Rosengren, B. Fagerberg, E. Hurt-Camejo, G. Camejo, HDL2 interference with LDL association with arterial proteoglycans: a possible athero-protective effect, Atherosclerosis 225 (1) (2012) 115–120.

46 J.J. Albers, A. Slez, J.L. Fleg, K.D. O’Brien, S.M. Marcovina, Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial, Atherosclerosis 251 (2016) 454–459.

47 Y. Zhang, S.M. Gordon, H. Xi, S. Choi, M.A. Paz, R. Sun, et al., HDL subclass proteomic analysis and functional implication of protein dynamic change during HDL maturation, Redox Biol. 24 (2019) 101222.

48 E. Zakiev, F. Rached, M. Lhomme, M. Darabi-Amin, M. Ponnaiah, P.H. Becker, et al., Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency, J. Clin. Lipidol. [Internet] 13 (3) (2019) 468–480, e8.

49 R. Schiavon, P. Battaglia, E. De Fanti, A. Fasolin, S. Biasioli, L. Targa, et al., HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism, Clin. Chim. Acta 324 (1–2) (2002) 39–44.